Recent additions to the mCRC armamentarium are the inhibitors of HER2 (rarely overexpressed in CRC, with a higher prevalence in RAS/BRAF–wild type tumors) and NTRK gene fusions (limited to cancers that are wild-type for KRAS, NRAS, and BRAF) [13,14]. The gene discussed is KRAS; the disease is colorectal carcinoma.